GI & Endoscopy

Here are three updates on GI companies to note:

John Inadomi, MD, is a professor of medicine and the head of gastroenterology at Seattle-based University of Washington.

After reporting non-statistically significant results in it a phase-II study, Cambridge, Mass.-based Seres Therapeutics is launching a revised phase-II study for its SER-109 Clostridium Difficile treatment.

London-based Technavio projects the global colonoscopy device market will grow to $2 billion by 2021 at an approximately 5 percent compound annual growth rate.

In collaboration with Lexington-based University of Kentucky, the National Cancer Institute is conducting educational colorectal cancer outreach services to increase screening rates throughout the state.

Beerse, Belgium-based Janssen Pharmaceuticals' Stelara, an alternative mechanism biologic, was the most exciting advancement to happen to inflammatory bowel disease in 2016, according to a Cambridge, Mass.-based Spherix Global Insights report.

A study published in Gut claims young overweight or obese men run a higher risk of developing severe liver disease or liver cancer later in life.

Knoxville, Tenn.-based Gastrointestinal Associates opened a new facility in Dowell Springs, Tenn., according to Knoxville News-Sentinel.

Sheila Crowe, MD, is a gastroenterology professor at UC San Diego and the president-elect of the American Gastroenterological Association.

Atlanta Gastroenterology Associates connected to the Georgia Health Information Network to efficiently exchange information with referring physicians, reduce cost and give physicians updated patient information.